Patient study to identify new disease characteristics

Since the beginning of the first funding period in 2009, the core project of the KKNMS is the cohort study in 1,000 patients with clinically isolated syndrome (CIS) or an early stage of multiple sclerosis. At the time of inclusion into the study the patients have not undergone therapy, and in the course of the study they will be categorized into three groups:

  • stable disease course without therapy
  • therapy with standard drug treatment
  • progressive disease course while undergoing standard drug treatment

The patients are followed up for at least 10 years by medical supervision and scientific observation. This means that clinical and paraclinical data are gathered, biomaterials are collected and MR imaging is evaluated. The investigators hope to discover new (epi-) genetic and biological traits characteristic of MS, so-called biomarkers. They provide important information, e.g. on how the disease will most likely develop in the individual patient and how patients respond to treatments. Furthermore, the classification of patients into different groups allows us to determine differences in the disease course between untreated and treated patients.

Strict adherence to ethical standards

Both the recruitment of study participants as well as the storage of biosamples collected later will be carried out in accordance with strict ethical standards. For this, standardized protocols which were developed in a subproject must be approved by the medical ethics commissions of each participating study center. All of the biosamples will be anonymized and registered in a central data bank.

This study will be coordinated by Prof. Dr. Ralf Gold (University of Bochum). The co-coordinator for statistics will be Prof. Dr. Andreas Ziegler (University of Lübeck) and IT support will be provided by Gisela Antony (University of Marburg).

 

Klinik für Neurologie, Universitätsklinikum Düsseldorf

Neurologische Klinik

2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
PI: Prof. Dr. Orhan Aktas

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PIs Studienzentrum: Prof. Dr. Hans-Peter-Hartung und Prof. Dr. Orhan Aktas

Universitätsmedizin Mainz, Klinik für Neurologie

Klinik für Neurologie

3.2 Brain network patterns as prognostic and therapy response markers in multiple sclerosis (MSNetworks)
PI: Prof. Dr. Frauke Zipp
Co-Pis: Prof. Dr. Sergiu Groppa, Dr. Felix Lüssi

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Frauke Zipp

Klinik für Neurologie und klinische Neurophysiologie Universitätsklinikum Augsburg

Neurologische Klinik und klinische Neurophysiologie

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
Assoziiertes Mitglied: Dr. Antonios Bayas

Institut für Klinische Neuroimmunologie Klinikum der LMU München, Großhadern

Institut für Klinische Neuroimmunologie

2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
PI: Prof. Dr. Tania Kümpfel

3.4 B-cells and antibody profiles (BIginMS)
PI: Prof. Dr. Edgar Meinl
Co-PI: Prof. Dr. Reinhard Hohlfeld

5.5 Improved assessment of disease phenotypes in multiple sclerosis models (PhenoModel)
PI: Prof. Dr. Martin Kerschensteiner

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Tania Kümpfel

Max-Planck-Institut für Psychiatrie

1.5 Biostatistical support and data analysis (Biostat)
Co-PI: Prof. Dr. Bertram Müller-Myhsok

4.2 Genetic determinants of MRI changes in MS (Gene-MRI)
Co-PI: Prof. Dr. Bertram Müller-Myhsok

4.3 Genetic determinants of cerebrospinal fluid parameters in multiple sclerosis (Gene-CSF)
Co-PI: Prof. Dr. Bertram Müller-Myhsok

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Frank Weber

Medizinische Hochschule Hannover, Klinik für Neurologie OE 7210

Neurologische Klinik

2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PI: Prof. Dr. Corinna Trebst

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Martin Stangel

Universitätsklinikum Marburg, Klinik und Poliklinik für Neurologie

Central Information Office:

1.2 IT platform for the Competence Network Multiple Sclerosis (CoreUnitIT)
PI: Dr. Gisela Antony

2.1 Prospective cohort study in clinically isolated syndrome and early multiple sclerosis (KKNMS-Kohorte)
Co-PI: Dr. Gisela Antony

2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PI: Dr. Gisela Antony

2.4 Extension and internationalization of REGIMS, an immune therapy register for the improvement of drug safety and treatment of patients with MS (REGIMS)
Co-PI: Dr. Gisela Antony

Universitätsklinikum Marburg, Klinik für Neurologie:

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: PD Dr. Björn Tackenberg

St. Josef Hospital, Klinikum der Ruhr-Universität Bochum, Klinik für Neurologie

Neurologische Universitätsklinik:

2.1 Prospective cohort study in clinically isolated syndrome and early multiple sclerosis (KKNMS-Kohorte)
PI: Prof. Dr. Ralf Gold
Co-PI: Dr. Anke Salmen

2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PIs: PD Dr. Kerstin Hellwig, Prof. Dr. Ingo Kleiter

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Ralf Gold

Institut für diagnostische und interventionelle Radiologie und Nuklearmedizin:

1.6 MRI Quality and Standards (MuSIQC)
PI: Prof. Dr. Carsten Lukas

4.2 Genetic determinants of MRI changes in MS (Gene-MRI)
Co-PI: Prof. Dr. Carsten Lukas

Klinikum rechts der Isar der Technischen Universität München, Neurologische Klinik und Poliklinik

Klinikum rechts der Isar
Klinik und Poliklinik für Neurologie

1.1 Central Network Coordination (CoreOffice)
PI: Claudia Borsanyi

1.3 Biomaterial Bank of the KKNMS (Biobank)
PI: Prof. Dr. med. Bernhard Hemmer

4.2 Genetic determinants of MRI changes in MS (Gene-MRI)
PI: Prof. Dr. Mark Mühlau

4.3 Genetic determinants of cerebrospinal fluid parameters in multiple sclerosis (Gene-CSF)
PI: Prof. Dr. Bernhard Hemmer
Co-PIs: Dr. Dorothea Buck

5.2 Interplay of antigen specific T cells and B cells in mouse models of neuromyelitis optica (T-B in NMO)
PI: Prof. Dr. Thomas Korn

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Bernhard Hemmer

Molekulare Neuroimmunologie, Neurologische Klinik, Universitätsklinikum Heidelberg

Neurologische Klinik
Sektion Molekulare Neuroimmunologie

2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PI: Prof. Dr. Brigitte Wildemann

3.5 Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response (ProgramMS)
Co-PI: Prof. Dr. Brigitte Wildemann

3.6 Predictive markers of imminent recurrence or rebound disease activity in MS patients switching immunotherapy (ReboundMS)
PI: Prof. Dr. Brigitte Wildemann
Co-PI: Dr. Jürgen Haas

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Brigitte Wildemann

Klinik und Poliklinik für Neurologie der Universität Ulm

Neurologische Universitätsklinik

3.6 Predictive markers of imminent recurrence or rebound disease activity in MS patients switching immunotherapy (ReboundMS)
Co-PI: Prof. Dr. Hayrettin Tumani

4.3 Genetic determinants of cerebrospinal fluid parameters in multiple sclerosis (Gene-CSF)
Co-PI: Prof. Dr. Hayrettin Tumani

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Hayrettin Tumani

Charité – Universitätsmedizin Berlin

Institut für Neuroimmunologie

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Friedemann Paul

Universitätsklinikum Erlangen

Neurologische Klinik
Neuroimmunologie

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Ralf Linker

Institut für Neuroimmunologie und Multiple Sklerose (UKE)

Molekulare Neurobiologie Hamburg (ZMNH)
Institut für Neuroimmunologie und Multiple Sklerose (INIMS)

2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PI: Dr. Jan-Patrick Stellmann

5.3 Modeling CD8+ T cell responses in multiple sclerosis (CD8Model)
PI: Prof. Dr. Manuel Friese

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Christoph Heesen

Klinik und Poliklinik für Neurologie, Universität Leipzig

Klinik und Poliklinik für Neurologie

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: PD Dr. Florian Then Bergh

Neurologische Poliklinik der Universität Rostock

Klinik für Neurologie und Poliklinik

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Uwe Zettl

Universitätsklinikum Tübingen, Zentrum für Neurologie, Hertie-Institut für klinische Hirnforschung, Abteilung Neurologie mit Schwerpunkt neurovaskuläre Erkrankungen

Allgemeine Neurologie

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Ulf Ziemann

Klinik für Neurologie mit Institut für Translationale Neurologie, Universitätsklinikum Münster

Universitätsklinikum – Department für Neurologie:

1.3 Biomaterial Bank of the KKNMS (Biobank)
Co-PI: Prof. Dr. Heinz Wiendl

3.1 Multi-parameter immune cell-profiling: identification of biosignatures to understand heterogeneity, prognosis and treatment response factors (ImmuneMS)
PI: Prof. Dr. Heinz Wiendl
Co-PIs: Prof. Dr. Luisa Klotz; Dr. Catharina Groß

3.5 Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response (ProgramMS)
PI: Prof. Dr. Dr. Sven Meuth
Co-PIs: Prof. Dr. Heinz Wiendl, Dr. Tobias Ruck

3.6 Predictive markers of imminent recurrence or rebound disease activity in MS patients switching immunotherapy (ReboundMS)
Co-PIs: Prof. Dr. Heinz Wiendl, Prof. Dr. Dr. Sven Meuth

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Heinz Wiendl

Institut für Epidemiologie und Sozialmedizin:

2.4 Extension and internationalization of REGIMS, an immune therapy register for the improvement of drug safety and treatment of patients with MS (REGIMS)
PI: Prof. Dr. Klaus Berger

MS-Kohortenstudie